459 related articles for article (PubMed ID: 10907648)
1. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma.
Vose JM; Bierman PJ; Lynch JC; Atkinson K; Juttner C; Hanania CE; Bociek G; Armitage JO
Biol Blood Marrow Transplant; 2001; 7(12):680-7. PubMed ID: 11787531
[TBL] [Abstract][Full Text] [Related]
3. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma.
Tricot G; Gazitt Y; Leemhuis T; Jagannath S; Desikan KR; Siegel D; Fassas A; Tindle S; Nelson J; Juttner C; Tsukamoto A; Hallagan J; Atkinson K; Reading C; Hoffman R; Barlogie B
Blood; 1998 Jun; 91(12):4489-95. PubMed ID: 9616143
[TBL] [Abstract][Full Text] [Related]
4. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.
Lemoli RM; Fortuna A; Motta MR; Rizzi S; Giudice V; Nannetti A; Martinelli G; Cavo M; Amabile M; Mangianti S; Fogli M; Conte R; Tura S
Blood; 1996 Feb; 87(4):1625-34. PubMed ID: 8608257
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
Vescio R; Schiller G; Stewart AK; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; DiPersio J; Anderson K; Berenson J
Blood; 1999 Mar; 93(6):1858-68. PubMed ID: 10068658
[TBL] [Abstract][Full Text] [Related]
6. Purified CD34+ Lin- Thy+ stem cells do not contain clonal myeloma cells.
Gazitt Y; Reading CC; Hoffman R; Wickrema A; Vesole DH; Jagannath S; Condino J; Lee B; Barlogie B; Tricot G
Blood; 1995 Jul; 86(1):381-9. PubMed ID: 7540887
[TBL] [Abstract][Full Text] [Related]
7. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
8. Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma.
Lemoli RM; Fortuna A; Raspadori D; Ventura MA; Martinelli G; Gozzetti A; Leopardi G; Ratta M; Cavo M; Tura S
Leuk Lymphoma; 1997 Dec; 26 Suppl 1():1-11. PubMed ID: 9570675
[TBL] [Abstract][Full Text] [Related]
9. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
10. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
Schiller G; Vescio R; Freytes C; Spitzer G; Sahebi F; Lee M; Wu CH; Cao J; Lee JC; Hong CH
Blood; 1995 Jul; 86(1):390-7. PubMed ID: 7540888
[TBL] [Abstract][Full Text] [Related]
11. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells in multiple myeloma: the issue of safety.
Sica S; Sorá F; Chiusolo P; Cicconi S; Piccirillo N; Cattani P; Laurenti L; Leone G
Exp Hematol; 2001 Jan; 29(1):1-2. PubMed ID: 11234735
[No Abstract] [Full Text] [Related]
12. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
[TBL] [Abstract][Full Text] [Related]
14. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
15. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
[TBL] [Abstract][Full Text] [Related]
16. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.
Gazitt Y; Tian E; Barlogie B; Reading CL; Vesole DH; Jagannath S; Schnell J; Hoffman R; Tricot G
Blood; 1996 Jan; 87(2):805-11. PubMed ID: 8555506
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
Hicks C; Isaacs A; Wong R; Chong BH
Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
[TBL] [Abstract][Full Text] [Related]
18. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34(+), CD34(+)38(-), and week-6 CAFC assays predict poor engraftment.
Robinson SN; Freedman AS; Neuberg DS; Nadler LM; Mauch PM
Exp Hematol; 2000 Dec; 28(12):1325-33. PubMed ID: 11146154
[TBL] [Abstract][Full Text] [Related]
19. G-CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma.
Mahé B; Milpied N; Hermouet S; Robillard N; Moreau P; Letortorec S; Rapp MJ; Bataille R; Harousseau JL
Br J Haematol; 1996 Feb; 92(2):263-8. PubMed ID: 8602984
[TBL] [Abstract][Full Text] [Related]
20. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: effect of the CD34+ cell dose.
Diaz MA; Vicent MG; Garcia-Sanchez F; Vicario JL; Madero L
Vox Sang; 2000; 79(3):145-50. PubMed ID: 11111232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
